The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-20-299, which uses the R21 grant mechanism.

Deadlines:

• Letter of Intent Deadlines: 30 days prior to the applicable receipt date
• Application Deadlines:  December 10, 2020, April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022; April 11, 2023

PAR-20-300 Expiration Date: New Date - April 12, 2023 per issuance of NOT-HD-22-031 (Original Date: December 10, 2022)